Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Ulinastatin on Postoperative Blood Loss and Hemostasis in Atrioventricular Valve Surgery with Cardiopulmonary Bypass

  • Park, Jae Bum (Department of Thoracic and Cardiovascular Surgery, Konkuk University School of Medicine) ;
  • Kim, Seong Hyop (Department of Anaesthesiology and Pain Medicine, Konkuk University School of Medicine) ;
  • Lee, Song Am (Department of Thoracic and Cardiovascular Surgery, Konkuk University School of Medicine) ;
  • Chung, Jin Woo (Department of Thoracic and Cardiovascular Surgery, Konkuk University School of Medicine) ;
  • Kim, Jun Seok (Department of Thoracic and Cardiovascular Surgery, Konkuk University School of Medicine) ;
  • Chee, Hyun Keun (Department of Thoracic and Cardiovascular Surgery, Konkuk University School of Medicine)
  • Received : 2012.10.15
  • Accepted : 2012.10.26
  • Published : 2013.06.05
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Cardiopulmonary bypass (CPB) induces variable systemic inflammatory reactions associated with major organ dysfunction via polymorphonuclear neutrophils (PMNs). Ulinastatin, a urinary trypsin inhibitor, inhibits PMN activity and reduces systemic inflammatory responses. The aim of this study is to evaluate the effect of ulinastatin on postoperative blood loss and laboratory changes in patients undergoing open heart surgery. Materials and Methods: Between January 2008 and February 2009, 110 patients who underwent atrioventricular valve surgery through right thoracotomy were divided into two groups. Patients received either 5,000 U/kg ulinastatin (ulinastatin group, n=41) or the equivalent volume of normal saline (control group, n=69) before aortic cross clamping. The primary end points were early coagulation profile changes, postoperative blood loss, transfusion requirements, and duration of intubation and intensive care unit stay. Results: There were no statistically significant differences between the two groups in early coagulation profile, other perioperative laboratory data, and postoperative blood loss with transfusion requirements. Conclusion: Administration of ulinastatin during operation did not improve the early coagulation profile, postoperative blood loss, or transfusion requirements of patients undergoing open heart surgery. In addition, no significant effect of ulinastatin was observed in major organs dysfunction, systemic inflammatory reactions, or other postoperative profiles.

Keywords

References

  1. Cremer J, Martin M, Redl H, et al. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 1996;61:1714-20. https://doi.org/10.1016/0003-4975(96)00055-0
  2. Murphy GJ, Angelini GD. Side effects of cardiopulmonary bypass: what is the reality? J Card Surg 2004;19:481-8. https://doi.org/10.1111/j.0886-0440.2004.04101.x
  3. Wan S, LeClerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. Chest 1997;112:676-92. https://doi.org/10.1378/chest.112.3.676
  4. Manfredi AA, Rovere-Querini P, Maugeri N. Dangerous connections: neutrophils and the phagocytic clearance of activated platelets. Curr Opin Hematol 2010;17:3-8. https://doi.org/10.1097/MOH.0b013e3283324f97
  5. Muramatu M, Mori S, Matsuzawa Y, Horiguchi Y, Nakanishi Y, Tanaka M. Purification and characterization of urinary trypsin inhibitor, UTI68, from normal human urine, and its cleavage by human uropepsin. J Biochem 1980;88: 1317-29. https://doi.org/10.1093/oxfordjournals.jbchem.a133100
  6. Ogawa M, Nishibe S, Mori T, Neumann S. Effect of human urinary trypsin inhibitor on granulocyte elastase activity. Res Commun Chem Pathol Pharmacol 1987;55:271-4.
  7. Okida M, Masako O, Maruya H, Higashi T, Yukaya H. Intraoperative changes in blood coagulation and the effectiveness of ulinastatin during liver resection. J Anesth 1991; 5:43-7. https://doi.org/10.1007/s0054010050043
  8. Ji HW, Chen L. Effects of ulinastatin on coagulation and platelet function in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. Zhonghua Yi Xue Za Zhi 2009;89:175-8.
  9. Kim DC, Chee HK, Song MG, et al. Comparative analysis of thoracotomy and sternotomy approaches in cardiac reoperation. Korean J Thorac Cardiovasc Surg 2012;45:225-9. https://doi.org/10.5090/kjtcs.2012.45.4.225
  10. Essell JH, Martin TJ, Salinas J, Thompson JM, Smith VC. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993;7:410-5. https://doi.org/10.1016/1053-0770(93)90161-D
  11. Hirose J, Ozawa T, Miura T, et al. Human neutrophil elastase degrades inter-alpha-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins. Biol Pharm Bull 1998;21: 651-6. https://doi.org/10.1248/bpb.21.651
  12. Nakatani K, Takeshita S, Tsujimoto H, Kawamura Y, Sekine I. Inhibitory effect of serine protease inhibitors on neutrophil- mediated endothelial cell injury. J Leukoc Biol 2001; 69:241-7.
  13. Lee JY, Lee JY, Chon JY, Moon HS, Hong SJ. The effect of ulinastatin on hemostasis in major orthopedic surgery. Korean J Anesthesiol 2010;58:25-30. https://doi.org/10.4097/kjae.2010.58.1.25
  14. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:552-9. https://doi.org/10.1016/0003-4975(93)91048-R
  15. Hu XH, Zhang HY, Ge YL, et al. Protective effects of ulinastatin against multiple organic damage after severe burn injury: experimental and clinic studies. Zhonghua Yi Xue Za Zhi 2005;85:2889-94.
  16. Sugita T, Watarida S, Katsuyama K, Nakajima Y, Yamamoto R, Mori A. Effect of a human urinary protease inhibitor (Ulinastatin) on respiratory function in pediatric patients undergoing cardiopulmonary bypass. J Cardiovasc Surg (Torino) 2002;43:437-40.
  17. Ueki M, Yokono S, Nogaya J, et al. Effects of ulinastatin on postoperative renal function after cardiopulmonary bypass. Masui 1995;44:691-7.
  18. Nakanishi K, Takeda S, Sakamoto A, Kitamura A. Effects of ulinastatin treatment on the cardiopulmonary bypass-induced hemodynamic instability and pulmonary dysfunction. Crit Care Med 2006;34:1351-7. https://doi.org/10.1097/01.CCM.0000215110.55899.AE
  19. Bingyang J, Jinping L, Mingzheng L, Guyan W, Zhengyi F. Effects of urinary protease inhibitor on inflammatory response during on-pump coronary revascularization: effect of ulinastatin on inflammatory response. J Cardiovasc Surg (Torino) 2007;48:497-503.
  20. Song JE, Kang WS, Kim DK, et al. The effect of ulinastatin on postoperative blood loss in patients undergoing open heart surgery with cardiopulmonary bypass. J Int Med Res 2011;39:1201-10. https://doi.org/10.1177/147323001103900408
  21. Mitsuhata H, Enzan K, Hasegawa J, Matsumoto S, Yabe M, Matsumoto J. Effects of ulinastatin on changes of plasma granulocyte elastase, myeloperoxidase and fibronectin during and after open heart surgery. Masui 1990;39:1164-71.

Cited by

  1. Effect of Urinary Protease Inhibitor (Ulinastatin) on Cardiopulmonary Bypass: A Meta-Analysis for China and Japan vol.9, pp.12, 2014, https://doi.org/10.1371/journal.pone.0113973
  2. Lack of Efficacy of Ulinastatin Therapy During Cardiopulmonary Bypass Surgery vol.128, pp.23, 2013, https://doi.org/10.4103/0366-6999.170364
  3. Ulinastatin attenuates vascular endothelial cell damage in pregnant women with severe pre-eclampsia vol.91, pp.3, 2013, https://doi.org/10.1590/0001-3765201920180746
  4. Ulinastatin reduces postoperative bleeding and red blood cell transfusion in patients undergoing cardiac surgery : A PRISMA-compliant systematic review and meta-analysis vol.99, pp.7, 2013, https://doi.org/10.1097/md.0000000000019184
  5. Effect of ulinastatin on post-operative blood loss and allogeneic transfusion in patients receiving cardiac surgery with cardiopulmonary bypass: a prospective randomized controlled study with 10-year vol.15, pp.1, 2013, https://doi.org/10.1186/s13019-020-01144-9